Is Caris Life Sciences, Inc. (CAI) a Buy, Sell, or Hold?
Caris Life Sciences, Inc.
NASDAQ:CAI
$17.46 USD
$0.51 (3.01%)
- Volume
- 6.33M
- Average Volume
- 2.77M
- Market Capitalization
- $4.94B
- P/E Ratio
- -11.22
- Dividend Yield
- 0.00%
- Price Target
- $23.50
- Year High
- $42.50
- Year Low
- $14.19
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.05
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | David Dean Halbert |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CAI |
| CUSIP | 142152107 |
| CIK | 0002019410 |
| Web | https://www.carislifesciences.com |
| Phone | 866 771 8946 |
| Currency | USD |
| Employees | 1846 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.73 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.05 |
| Quick Ratio | 7.05 |
| Cash Ratio | 5.71 |
Sales & Book Value
| Annual Sales | $812.03M |
| Price / Sales | 5.44 |
| Cash Flow | 0.44 |
| Price / Cash Flow | 39.98 |
| Price / Book | 8.31 |
Price Target and Rating
| Average Stock Price Forecast | $23.50 |
| High Stock Price Forecast | $32.00 |
| Low Stock Price Forecast | $21.00 |
| Forecast Upside/Downside | -25.70% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.9 |
| Trailing P/E Ratio | -11.22 |
| PEG Ratio | 0.04 |
| P/E Growth | 0.04 |
| Net Income | $-537.96M |
| Net Margin | 3.75% |
| Pretax Margin | 3.73% |
| Return on Equity | 6.47% |
| Return on Assets | 2.92% |
Financials Score
| AltmanZ Score | 3.92 |
| Piotroski Score | 7.00 |
| Working Capital | 870.28M |
| Total Assets | 1.16B |
| Ebit | 90.73M |
| Market Cap | 4.8B |
| Total Liabilities | 568.9M |
Poll Results
About Caris Life Sciences, Inc. (NASDAQ:CAI) Stock
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Establishe ... d in 2008, the company maintains its corporate headquarters in Irving, Texas.
Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
2026-07-14 08:30:00
IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic hormone-sensitive prostate cancer) who are eligible for the newly approved biomarker-guided therapy, representing a significant advancement in precision oncology for this disease.
2026-07-01 08:30:00
Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithmsdelivers superior performance to existing cancer detection technologies IRVING, Texas, July 1, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the commercial launch of Caris Detect™, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages. Caris Detect is engineered to push the boundaries of what is possible in early cancer detection.
2026-06-24 09:07:00
ALLENTOWN, Pa., June 24, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, was awarded a statewide contract with the Virginia Information Technologies Agency (VITA) to provide Security Operations Center (SOC) services to local government entities across the Commonwealth.
CAI Named to Newsweek's America's Greatest Workplaces in Tech 2026
2026-06-17 09:06:00
ALLENTOWN, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, today announced it has been named to Newsweek's America's Greatest Workplaces in Tech 2026 list.
Caris Life Sciences Announces Dual Listing on NYSE Texas
2026-06-16 08:30:00
IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texas effective on June 17, 2026, further expanding its presence in the public markets. Caris' shares will continue to be listed and trade on its primary exchange, the NASDAQ, with a dual listing on the NYSE Texas under the same CAI ticker symbol, expected to provide additional exposure to investors, particularly within Texas and the broader U.S. market.
Caris Life Sciences: The Discount To Peers Looks Hard To Ignore
2026-06-12 07:57:50
Caris Life Sciences is rated a buy, combining 79% Q1 2026 revenue growth, 65%+ gross margins, and positive free cash flow. CAI's genomic database of over one million cases underpins future products like Caris Detect, offering a potential competitive edge. At 5x EV/Sales, CAI trades at a discount to peers despite superior growth and profitability, further supported by a $100M buyback.
2026-06-08 15:48:32
Caris Life Sciences, Inc. (CAI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Caris Life Sciences Announces Share Repurchase Program
2026-06-08 08:30:00
IRVING, Texas, June 8, 2026 /PRNewswire/ -- Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that its Board of Directors has authorized a share repurchase program for up to $100 million of the Company's outstanding common stock. Under the repurchase program, the Company may repurchase shares from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
Frequently Asked Questions
-
What is the current Caris Life Sciences, Inc. (CAI) stock price?
-
Caris Life Sciences, Inc.(NASDAQ:CAI) stock price is $17.46 in the last trading session. During the trading session, CAI stock reached the peak price of $42.5 while $14.19 was the lowest point it dropped to. The percentage change in CAI stock occurred in the recent session was 3.01% while the dollar amount for the price change in CAI stock was $0.51.
-
CAI's industry and sector of operation?
-
The NASDAQ listed CAI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CAI?
-
Valeriy Domenyuk | Senior Vice President & Chief Technology Officer
Brian J. Brille | Executive Vice Chairman & Executive Vice President
Luke Power | Senior Vice President, Chief Financial Officer & Chief Accounting Officer
Narendra Chokshi | Senior Vice President of Corporate Development
Ginger Appleberry | Senior Vice President, Deputy General Counsel & Chief Compliance Officer -
How many employees does CAI have?
-
Number of CAI employees currently stands at 1846. CAI operates from 750 West John Carpenter Freeway, Irving, TX 75039, US.
-
Link for CAI official website?
-
Official Website of CAI is: https://www.carislifesciences.com
-
How do I contact CAI?
-
CAI could be contacted at phone #866 771 8946 and can also be accessed through its website. CAI operates from 750 West John Carpenter Freeway, Irving, TX 75039, US.
-
How many shares of CAI are traded daily?
-
The average number of CAI shares traded daily for last 3 months was 2.77M.
-
What is the market cap of CAI currently?
-
The market value of CAI currently stands at $4.94B with its latest stock price at $17.46